CD4+CD25+CD127loCD45RA+ Tregs might be a candidate for a Treg therapy for CD in future clinical trials.31 Tregs have been proposed as a potential therapy for IBD, but the remission and side effects of novel IBD therapies such as long‐term maintain therapies are still unknown.32 The first trial of the effectiveness of Tregs for CD recently reported 40% of patients improved after 8 weeks of clinical administration, including a decrease of CRP and fecal calprotectin.33 Then, Tregs might be promising candidates for the treatment of CD. This evidence concerns the gene CD4 and inflammatory bowel disease.